drugset / Trial / NCT03768713

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713

RandomizedParallel-groupDouble-blindBasic science

Summary

This study aims to evaluate the effect of Suvorexant on sympathetic nerve activity and baroreflex function in subject with chronic insomnia. The investigator's central hypothesis is that Suvorexant will reduce sympathetic nerve activity and improve baroreflex function when compared to placebo.

Timeline

Start
2019-04-18
Primary completion
2022-12
Completion
2023-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 20 mg Oral

Indications